Edition:
United Kingdom

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

135.57USD
7:35pm BST
Change (% chg)

$-0.08 (-0.06%)
Prev Close
$135.65
Open
$135.17
Day's High
$135.85
Day's Low
$134.53
Volume
183,402
Avg. Vol
639,430
52-wk High
$149.17
52-wk Low
$102.21

Select another date:

Thu, Apr 26 2018

BRIEF-Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study

* ALEXION REPORTS FIRST QUARTER 2018 RESULTS AND POSITIVE TOPLINE DATA FROM ALXN1210 PHASE 3 PNH SWITCH STUDY

BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil

* ALEXION PROVIDES STATEMENT ON SUPERIOR COURT OF JUSTICE (STJ) DECISION IN BRAZIL INVOLVING SOLIRIS® (ECULIZUMAB)

Deals of the day-Mergers and acquisitions

April 11 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:

Biotech M&A rolls on as Alexion snaps up Wilson for $855 million

Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.

Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln

Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.

UPDATE 2-Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln

* U.S. company says first step in rebuilding pipeline (Adds latest shares, analyst reaction)

Alexion to buy Swedish biotech Wilson Therapeutics for $855 mln

April 11 Alexion Pharmaceuticals said on Wednesday it had agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million) to boost its line-up of rare disease drugs.

BRIEF-Alexion To Acquire Wilson Therapeutics

* SAYS ALEXION WILL ACQUIRE WILSON THERAPEUTICS THROUGH A TENDER OFFER

BRIEF-Alexion Pharmaceuticals Says CEO Ludwig Hantson's Total FY 2017 Compensation Was $15.3 Mln

* ALEXION PHARMACEUTICALS SAYS CEO LUDWIG HANTSON'S TOTAL FY 2017 COMPENSATION WAS $15.3 MILLION - SEC FILING

Alexion's second rare blood disorder drug could fortify future revenue

Alexion Pharmaceuticals Inc said its experimental drug to treat a rare blood disorder showed in an eagerly awaited study that it was not inferior to its flagship drug, Soliris, paving the way for the company to establish a dominant position in the market as competition looms.

Select another date: